This Article Full Text Full Text (PDF) Online Supplement All Versions of this Article: 200602-255OCv1 175/4/330    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sharafkhaneh, A. Articles by Boriek, A. M. Search for Related Content PubMed PubMed Citation Articles by Sharafkhaneh, A. Articles by Boriek, A. M.

The Confounding Effects of Thoracic Gas Compression on Measurement of Acute Bronchodilator Response

¹ Baylor College of Medicine, Houston, Texas; ² Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; and ³ UT Southwestern Medical Center, Dallas, Texas

Correspondence and requests for reprints should be addressed to Amir Sharafkhaneh, M.D., Assistant Professor of Medicine, Baylor College of Medicine, M.E.D. VAMC, Bldg. 100 (111i), 2002 Holcombe Blvd., Houston, TX 77030. E-mail: amirs{at}bcm.tmc.edu

Rationale: Improvement in FEV₁ is a main endpoint in clinical trials assessing the efficacy of bronchodilators. However, the effect of bronchodilators on maximal expiratory flow may be confounded by thoracic gas compression (TGC).

Objective: To determine whether TGC confounds effect of albuterol on FEV₁.

Methods: We evaluated the response to albuterol inhalation in 10 healthy subjects, 9 subjects with asthma, and 15 subjects with chronic obstructive pulmonary disease (COPD) with mean (SD) age in years of 38 (SD, 11), 45 (SD, 11), and 64 (SD, 8), respectively. Lung mechanics were measured at baseline and 20 minutes after inhalation of 180 µg of albuterol. We then applied a novel method to calculate FEV₁ corrected for the effect of TGC (NFEV₁).

Results: Prior to albuterol administration, NFEV₁ was significantly higher than FEV₁. However, post–albuterol inhalation, FEV₁ increased more than NFEV₁ because of reduced TGC. In multiple regression analysis, the changes in TGC, inspiratory lung resistance, and ratio of residual volume to total lung capacity postalbuterol predicted more than 75% of FEV₁ improvement in patients with COPD.

Conclusion: Improvements in FEV₁ after albuterol in patients with COPD are due to reduction of lung resistance, hyperinflation, and TGC. The latter is negligible during tidal breathing. Thus, although reduction of lung resistance and hyperinflation may result in improved dyspnea with a bronchodilator, the contribution of TGC reduction to improvement of FEV₁ may not exert any meaningful clinical effect during tidal breathing. This fact has to be taken into consideration when assessing the efficacy of new bronchodilators.

Key Words: FEV₁ • chronic obstructive pulmonary disease • asthma • lung mechanics • albuterol

AT A GLANCE COMMENTARY Scientific Knowledge on the Subject Lung function is used to evaluate response to therapy. However, confounding factors, including thoracic gas compression, may affect change in lung function with therapy. What This Study Adds to the Field Thoracic gas compression may confound effect of bronchodilators on lung function. Improvements in FEV1 after inhaled -adrenergic agents in COPD are due to reduction in lung resistance, hyperinflation, and thoracic gas compression.

 

This article has been cited by other articles:

				W. C. Moore Update in Asthma 2007 Am. J. Respir. Crit. Care Med., May 15, 2008; 177(10): 1068 - 1073. [Full Text] [PDF]